Tencent Investment and Guoxin Investment, a state capital investor in Shanghai, have jointly led a Series E funding round of 700 million yuan ($97.4 million) in Chinese biopharmaceutical firm Evopoint Biosciences.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
